UBS ASSET MANAGEMENT AMERICAS INC - KARYOPHARM THERAPEUTICS INC ownership

KARYOPHARM THERAPEUTICS INC's ticker is KPTI and the CUSIP is 48576U106. A total of 170 filers reported holding KARYOPHARM THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.86 and the average weighting 0.2%.

Quarter-by-quarter ownership
UBS ASSET MANAGEMENT AMERICAS INC ownership history of KARYOPHARM THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$356,4320.0%91,6280.0%0.00%
Q1 2023$356,432
+26.5%
91,628
+10.6%
0.00%
Q4 2022$281,775
-99.9%
82,875
+15.1%
0.00%
Q3 2022$393,238,000
+22.3%
72,022
+1.1%
0.00%
Q2 2022$321,433,000
-29.8%
71,271
+14.7%
0.00%
Q1 2022$457,824,000
-22.4%
62,120
-32.3%
0.00%
Q4 2021$589,766,000
+20.1%
91,721
+8.7%
0.00%
Q3 2021$491,167,000
-43.6%
84,3930.0%0.00%
Q2 2021$870,936,000
+48.8%
84,393
+51.7%
0.00%
Q1 2021$585,174,000
-39.9%
55,625
-11.5%
0.00%
Q4 2020$973,383,000
+32.6%
62,880
+25.1%
0.00%
Q3 2020$733,825,000
-25.4%
50,262
-3.3%
0.00%
-100.0%
Q2 2020$984,179,000
-1.5%
51,963
-0.1%
0.00%0.0%
Q1 2020$999,228,000
-20.0%
52,016
-20.2%
0.00%0.0%
Q4 2019$1,249,424,000
+139.9%
65,176
+20.4%
0.00%
Q3 2019$520,749,000
+222.3%
54,132
+100.7%
0.00%
Q2 2019$161,586,000
+106.4%
26,976
+101.2%
0.00%
Q1 2019$78,285,000
-37.7%
13,4050.0%0.00%
Q4 2018$125,605,000
+123042.2%
13,405
+27.7%
0.00%
Q3 2016$102,000
+45.7%
10,5000.0%0.00%
Q2 2016$70,000
-25.5%
10,5000.0%0.00%
Q1 2016$94,000
-32.4%
10,5000.0%0.00%
Q4 2015$139,000
+25.2%
10,5000.0%0.00%
Q3 2015$111,000
-61.2%
10,5000.0%0.00%
Q2 2015$286,000
-91.6%
10,500
-90.6%
0.00%
-100.0%
Q1 2015$3,416,000
-18.7%
111,600
-0.6%
0.00%
-25.0%
Q4 2014$4,203,000
+1385.2%
112,300
+1286.4%
0.00%
Q3 2014$283,000
-80.3%
8,100
-82.6%
0.00%
-100.0%
Q1 2014$1,439,000
+34.1%
46,600
-0.4%
0.00%
+100.0%
Q4 2013$1,073,00046,8000.00%
Other shareholders
KARYOPHARM THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
AIGH Capital Management LLC 1,773,474$2,376,4561.12%
AlphaCentric Advisors LLC 1,125,000$1,507,5000.86%
Tejara Capital Ltd 1,077,388$1,443,7000.82%
Palo Alto Investors LP 5,675,876$7,605,6740.72%
Birchview Capital, LP 571,832$766,2550.65%
Altium Capital Management LP 740,000$991,6000.52%
Avidity Partners Management LP 8,298,570$11,120,0840.45%
Worth Venture Partners, LLC 445,981$597,6150.36%
SILVERARC CAPITAL MANAGEMENT, LLC 561,955$753,0200.23%
DAFNA Capital Management LLC 192,678$258,1890.08%
View complete list of KARYOPHARM THERAPEUTICS INC shareholders